Payment Terms for Intermediates: 7 Buyer Mistakes to Avoid
This guide compares T/T, L/C, D/P and D/A for pharmaceutical intermediate purchases, with worked costs on a $60,000 order and the seven mistakes buyers make.
4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide;Finerenone Intermediates
CAS:1050477-27-4
Chemical Formula:C21H22N4O3
Molecular Weight:378.42
Availability: R&D; Commercialization
⬤ CAS No.1050477-27-4
⬤ Packaging type:
20kg barrel;5kg barrel;1kg bag;500g bag ; Customized Packaging
| Product Name | (Rac)-Finerenone |
| CAS No. | 1050477-27-4 |
| Chemical Formula | C21H22N4O3 |
| Molecular Weight | 378.42 |
| EINECS | 810-201-2 |
| Related Categories | Finerenone Intermediate |
| Melting point | 140-142 °C (decomp) |
| Specific rotation | D20 -31.5° (c = 1.2 in water) |
| Storage conditions | 20°C |
| Color | White |
| PH | About 3.0 (50mg/mL in water) |
| Note | This product is strictly designated as a non-pharmaceutical chemical intermediate and must be used exclusively for industrial synthesis purposes |
| Core drug synthesis | Used to synthesize Finerenone API |
| R&D and process optimization | Stereochemical studies;Process scale-up verification |
| Expanding application areas | Development of novel MR antagonists; Research on metabolic diseases |
Reliable Global Partner
“Tianming Pharmaceutical has redefined reliability for us. Their ability to deliver high-potency APIs and intermediates under tight deadlines—is unmatched. The team’s transparency in documentation and proactive updates make them a stress-free partner. A true backbone for our operations!”
March 18, 2024
Outstanding Technical Guidance
“Few suppliers align so perfectly with EU GMP requirements. Tianming’s commitment to audit-ready quality systems, batch traceability, and purity consistency has streamlined our production processes. Their diligence eliminates regulatory risks—a rare advantage in today’s market.”
February 15, 2024
Beyond Supplier, A Solutions Partner
“Tianming’s technical team doesn’t just deliver materials—they solve problems. When we faced stability challenges with a niche compound, their scientists proposed a tailored purity adjustment that saved our project timeline. Their agility transforms obstacles into opportunities.”
June 15, 2024
Strategic Growth Ally
“Over 5+ years, Tianming has consistently adapted to our evolving needs—whether scaling volumes or supporting custom synthesis projects. Their ethical pricing models and long-term vision make them more than a vendor; they’re integral to our competitive edge.”
April 27, 2024
This guide compares T/T, L/C, D/P and D/A for pharmaceutical intermediate purchases, with worked costs on a $60,000 order and the seven mistakes buyers make.
An impurity absent from a Certificate of Analysis is not necessarily absent from the process — it may simply have been purged downstream. This guide explains impurity fate mapping, purge factors, ICH M7 Option 4, and the five documents buyers should request.
This checklist shows buyers how to qualify a second supplier in six steps — documentation, batch consistency, quality agreements, and activation triggers included.
Manufacturer and supplier of pharmaceutical APIs and intermediates. Contact us for technical support and sourcing solutions.